Anti-Hu CD38 FITC

• Catalog Number: orb2281308
• Category: Antibodies
• Description: The mouse monoclonal antibody HB7 (HB-7) recognizes an extracellular epitope within amino acids 273-285 of human CD38, a 45 kDa type II transmembrane glycoprotein strongly expressed mainly on plasma cells and activated T and B lymphocytes; it is an antigenic marker of lymphoid cells. Its binding is blocked by daratumumab
• Clonality: Monoclonal
• Clone Number: HB7
• Tested applications: FC, ICC, WB
• Reactivity: Human
• Isotype: Mouse IgG1 kappa
• Immunogen: BJAB cell line
• Dilution range: Flow cytometry: The reagent is designed for analysis of human blood cells using 4 μl reagent / 100 μl of whole blood or 106 cells in a suspension. The content of a vial (0.4 ml) is sufficient for 100 tests
• Form/Appearance: Stabilizing phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide
• Purity: Purified antibody is conjugated with fluorescein isothiocyanate (FITC) under optimum conditions and unconjugated antibody and free fluorochrome are removed by size-exclusion chromatography
• Conjugation: FITC
• Target: CD38
• Entrez: 952
• UniProt ID: P28907
• Storage: Store at 2-8°C. Protect from prolonged exposure to light. Do not freeze
• Buffer/Preservatives: Stabilizing phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide
• Alternative names: ADPRC1, cADPr hydrolase 1, T10, NAD(+) nucleosidas
• Background: CD38 (NAD+ glycohydrolase) is a type II transmembrane glycoprotein able to induce activation, proliferation and differentiation of mature lymphocytes and mediate apoptosis of myeloid and lymphoid progenitor cells. Another role of CD38 is provided by enzymatic activity of its extracellular part. CD38 acts as NAD+ glycohydrolase converting NAD+ into ADP-ribose, as ADP-ribosyl cyclase producing cADPR and as cADPR hydrolase, thus affecting levels of calcium-mobilizing metabolites. ADPR produced by CD38 serves as an important second messenger of neutrophil and dendritic cell migration. CD38 belongs to markers of B cell subsets, leukemia, and a target of immunotherapy in myeloma treatment
• Note: For research use only
• Application notes: Unconjugated version: orb1952612
• Expiration Date: 12 months from date of receipt.

Analysis of the antibody staining profile was performed on blood leukocytes isolated from buffy coats. Mouse monoclonal anti-human CD38 FITC antibody (clone HB7) was used in concentration 0.5 µg/ml in stained blood sample (2 x 106 cells)

Analysis of the antibody staining profile was performed on blood leukocytes isolated from buffy coats. Mouse monoclonal anti-human CD38 FITC antibody (clone HB7) in concentration 0.5 µg/ml in stained stained blood sample (2 x 106 cells) and Mouse monoclonal anti-human CD27 Pacific Blue™ antibody (clone LT27) was used in concentration 2 µg/ml, respectively

Analysis of the antibody staining profile was performed on blood leukocytes isolated from buffy coats. Mouse monoclonal anti-human CD38 FITC antibody (clone HB7) in concentration 0.5 µg/ml in stained stained blood sample (2 x 106 cells) and Mouse monoclonal anti-human CD138 APC antibody (clone MI15) in concentration 2 µg/ml, respectively

Analysis of the antibody staining profile was performed on blood leukocytes isolated from buffy coats. Suspension of blood leukocytes (2 x 106 cells) was added to the mixture of CD38 FITC antibody (clone HB7, 0.5 µg/ml in stained blood sample), backbone antibody conjugates and Monocyte Blocking Buffer, vortexed and incubated for 20 min. Stained sample was fixed with 2 ml of 10× diluted EXCELLYSE Easy solution for 10 min. Finally, samples were centrifuged (670 g, 5 min.), supernatant removed and the cell pellet was resuspended in 200 µl of PBS for acquisition